pbi-4050
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2015 (NCT02562573)
Timeline
Indications
Mechanism of action
- Free fatty acid receptor 1INHIBITOR
FFAR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pbi-4050
- pbi-4050
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05349435 | Phase 1 | May 13, 2022 | Liminal BioSciences Ltd. |
| NCT03637049 | Phase 1 | Jul 17, 2018 | Celerion, ProMetic Life Sciences |
| NCT03184584 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2017 | ProMetic Life Sciences |
| NCT03081598 | Phase 2 | May 29, 2017 | ProMetic Life Sciences |
| NCT02955888 | Phase 2 | Jan 3, 2017 | ProMetic Life Sciences |
| NCT02739217 | Phase 2 | Dec 1, 2015 | ProMetic Life Sciences, Queen Elizabeth Hospital NHS Foundation Trust |
| NCT02538536 | Phase 2 | Jul 1, 2015 | ProMetic Life Sciences |
| NCT02562573 | Phase 2 | May 1, 2015 | ProMetic Life Sciences |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ProMetic Life Sciences | For profit | 7 | 7 | 3 | 2015 |
| Celerion | For profit | 1 | 0 | 1 | 2018 |
| Liminal BioSciences Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Queen Elizabeth Hospital NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1